VAL 201

Drug Profile

VAL 201

Alternative Names: VAL-201

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Research Technology
  • Developer ValiRx
  • Class Peptides
  • Mechanism of Action DNA synthesis inhibitors; Genetic transcription inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer; Solid tumours
  • Preclinical Endometriosis

Most Recent Events

  • 22 Mar 2018 ValRix receives patent allowance for VAL 201 in Europe , prior to March 2018
  • 18 Dec 2017 Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee approves the expansion of a phase I/II dose escalation study in Prostate Cancer and Solid tumours in United Kingdom
  • 07 Oct 2016 Efficacy and adverse events data from a phase-I/II trial in Solid tumours presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top